Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB) |
Whywhenwhohow (talk | contribs) update infobox, links, portal; needs references |
||
Line 1: | Line 1: | ||
{{unreferenced}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = 462265233 |
| verifiedrevid = 462265233 |
||
| IUPAC_name = 5-[(2''Z'')-2-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazino]-2-hydroxybenzoic acid |
|||
| image = Olsalazine.svg |
| image = Olsalazine.svg |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Dipentum |
| tradename = Dipentum |
||
| Drugs.com = {{drugs.com|monograph| |
| Drugs.com = {{drugs.com|monograph|olsalazine-sodium}} |
||
| MedlinePlus = a601088 |
| MedlinePlus = a601088 |
||
| DailyMedID = Olsalazine |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
| pregnancy_AU = C |
|||
| pregnancy_US = C<!-- A / B / C / D / X --> |
|||
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Olsalazine (Dipentum) Use During Pregnancy | website=Drugs.com | date=6 September 2019 | url=https://www.drugs.com/pregnancy/olsalazine.html | access-date=9 October 2020}}</ref> |
|||
| pregnancy_US = C |
|||
| pregnancy_US_comment = <ref name="Drugs.com pregnancy" /> |
|||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = S4 |
||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = |
| legal_UK = POM |
||
| legal_US = Rx-only |
| legal_US = Rx-only |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = [[Oral administration|By mouth]] |
||
| ATC_prefix = A07 |
|||
⚫ | |||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
Line 23: | Line 30: | ||
| elimination_half-life = 0.9 hours |
| elimination_half-life = 0.9 hours |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| index2_label = as salt |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 15722-48-2 |
| CAS_number = 15722-48-2 |
||
| |
| PubChem = 22419 |
||
⚫ | |||
| PubChem = 6003770 |
|||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = DB01250 |
| DrugBank = DB01250 |
||
Line 36: | Line 43: | ||
| UNII = ULS5I8J03O |
| UNII = ULS5I8J03O |
||
| KEGG_Ref = {{keggcite|changed|kegg}} |
| KEGG_Ref = {{keggcite|changed|kegg}} |
||
| KEGG = |
| KEGG = D08295 |
||
| KEGG2_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG2 = D00727 |
|||
| ChEBI_Ref = |
|||
| ChEBI = |
|||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = |
| ChEMBL = 425 |
||
| NIAID_ChemDB = |
|||
| PDB_ligand = |
|||
| synonyms = |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| chemical_formula = |
|||
| C=14 | H=10 | N=2 | O=6 |
| C=14 | H=10 | N=2 | O=6 |
||
| smiles = O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2 |
| smiles = O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2 |
||
Line 49: | Line 63: | ||
}} |
}} |
||
'''Olsalazine''' is an anti-inflammatory |
'''Olsalazine''' is an anti-inflammatory medication used in the treatment of [[inflammatory bowel disease]] such as [[ulcerative colitis]]. It is sold under the brand name '''Dipentum'''. |
||
The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt. |
The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt. |
||
Line 64: | Line 78: | ||
The Australian biotech company [[Giaconda (pharmaceutical company)|Giaconda]] has developed a combination therapy for treating constipation-predominant [[irritable bowel syndrome]] that uses olsalazine and the anti-[[gout]] drug [[colchicine]]. |
The Australian biotech company [[Giaconda (pharmaceutical company)|Giaconda]] has developed a combination therapy for treating constipation-predominant [[irritable bowel syndrome]] that uses olsalazine and the anti-[[gout]] drug [[colchicine]]. |
||
== |
== References == |
||
{{reflist}} |
|||
*[http://www.olsalazine.com/ Olsalazine official site] |
|||
*[http://www.medicinenet.com/olsalazine/article.htm Medicine Net] |
|||
== External links == |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/olsalazine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Olsalazine }} |
|||
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} |
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} |
||
{{Portal bar | Medicine}} |
|||
[[Category:Gastroenterology]] |
[[Category:Gastroenterology]] |
Revision as of 03:13, 9 October 2020
Clinical data | |
---|---|
Trade names | Dipentum |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601088 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.494 |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Olsalazine is an anti-inflammatory medication used in the treatment of inflammatory bowel disease such as ulcerative colitis. It is sold under the brand name Dipentum.
The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.
Like balsalazide, olsalazine is believed to deliver mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Other indications
The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine.
References
- ^ a b "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
External links
- "Olsalazine". Drug Information Portal. U.S. National Library of Medicine.